The Effect of Calcium Supplementation on Premenstrual Syndrome of Female students

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201309296888N4

Enrollment

Registered

2013-12-20

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified. Symptoms and signs involving cognition, perception, emotional state and behaviour

Interventions

Intervention 1: Intervention group: Prescription oral Calcium (500 mg/daily) for two months. Intervention 2: Control group: Prescription Placebo for two months.

Treatment - Drugs

Intervention group: Prescription oral Calcium (500 mg/daily) for two months.

Control group: Prescription Placebo for two months.

Eligibility

Sex/Gender

Female

Age

17 Years to 44 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Student; Having premenstrual syndrom; Lack of alleregy to drugs, Exclusion criteria: Women with age below 17 and above 44 years; Pregnancy; Alleregy to drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Premenstrual syndrome. Timepoint: Two months. Method of measurement: Questionaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Shobeiri

Hamadan University of Medical Sciences

shobeiri@umsha.ac.ir+98 81 1838 0150

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026